A new carbapenem antibiotic, meropenem, was shown to be active against a large number of Gram-positive bacteria. The drug inhibited penicillinase-positive and -negative, methicillin-susceptible staphylococti equally well. Among the comparative antimicrobials examined, only Af-formimidoyl-thienamycin (imipenem) was two to four times more active than meropenem. Compared with vancomycin or methicillin, meropenem was 10-20 times more active. Strains of 11 species of streptococci were highly susceptible to meropenem; the geometric mean MICs of the drug for these species ranged from 0-01 to 0-04 mg/1. The agent, however, only had moderate activity against Enterococcus faecalis (mean MIC 5 mg/1) and Ent.faecium (mean MIC 11-6 mg/1). Among Corynebacterium jeikeium, strains were encountered that showed susceptibility to meropenem but resistance to imipenem and other /Jlactams. Strains of other corynebacteria, Rhodococcus equi, Erysopelothrix rhusiopathiae, Listeria monocytogenes, and Bacillus spp. all were highly susceptible to meropenem (mean MICs 0-04-0-17 mg/1). Although methicillin-resistant staphylococci were inhibited by concentrations of 1-2 mg/1 of meropenem in agar dilution tests, such strains showed heteroresistance in population studies, as is typical for all /J-lactam antibiotics. In addition, the biochemical correlate of methicillin-resistance, penicillin-binding protein 2', showed low affinity for meropenem, similar to that for imipenem. Meropenem was as bactericidal as imipenem and comparative bactericidal antimicrobials in killing-curve experiments. Strains of Ent.faecium, C. jeikeium, and L. monocytogenes were killed at a slower rate than streptococci or staphylococci.